Holen Sie sich die Stockscreener-App
10.39
2.81%
-0.30
Handel nachbörslich:
10.59
0.20
+1.92%
Schlusskurs vom Vortag:
$10.69
Offen:
$10.66
24-Stunden-Volumen:
240.48K
Relative Volume:
1.51
Marktkapitalisierung:
$225.43M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-11.12%
1M Leistung:
-35.39%
6M Leistung:
-19.21%
1J Leistung:
+0.00%
1-Tages-Spanne:
$9.90
$10.74
1-Wochen-Bereich:
$9.90
$12.16
52-Wochen-Spanne:
$4.88
$19.58
Aardvark Therapeutics Inc Stock (AARD) Company Profile
Firmenname
Aardvark Therapeutics Inc
Sektor
Branche
Telefon
(858) 225-7696
Adresse
4370 LA JOLLA VILLAGE DRIVE, SAN DIEGO
Vergleichen Sie AARD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AARD
Aardvark Therapeutics Inc
|
10.39 | 231.90M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Aardvark Therapeutics Inc Stock (AARD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-29 | Eingeleitet | Stifel | Buy |
| 2025-06-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-10 | Eingeleitet | BofA Securities | Buy |
| 2025-03-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-03-10 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-03-10 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Aardvark Therapeutics Inc Aktie (AARD) Neueste Nachrichten
Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Aardvark Therapeutics (Nasdaq: AARD) grants inducement options totaling 88,217 shares - Stock Titan
Real time social sentiment graph for Aardvark Therapeutics Inc.Weekly Market Report & Long Hold Capital Preservation Tips - newser.com
Is Aardvark Therapeutics Inc. forming a reversal patternEarnings Performance Report & Weekly Stock Performance Updates - newser.com
Will Aardvark Therapeutics Inc. stock attract ESG investorsNew Guidance & Intraday High Probability Alerts - newser.com
Aardvark Therapeutics (NASDAQ: AARD) sets Nov 11 & Nov 24 investor talks; live webcasts - Stock Titan
Is Aardvark Therapeutics Inc. stock undervalued vs historical averagesTrade Volume Report & Risk Controlled Daily Trade Plans - newser.com
Why Aardvark Therapeutics Inc. stock is seen as undervaluedQuarterly Growth Report & Free Safe Capital Growth Stock Tips - newser.com
Analyzing Aardvark Therapeutics Inc. with multi timeframe charts2025 Top Gainers & Reliable Volume Spike Alerts - newser.com
Will Aardvark Therapeutics Inc. stock reach Wall Street targetsJuly 2025 Action & Target Return Focused Picks - newser.com
Is Aardvark Therapeutics Inc. stock attractive for income investorsJobs Report & Verified Momentum Stock Ideas - newser.com
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Will Aardvark Therapeutics Inc. stock beat EPS estimates2025 Sector Review & Real-Time Buy Signal Notifications - newser.com
Using AI based signals to follow Aardvark Therapeutics Inc.Trade Analysis Summary & Real-Time Price Movement Reports - newser.com
Is Aardvark Therapeutics Inc. forming a bottoming baseVolume Spike & Weekly Breakout Watchlists - newser.com
Is Aardvark Therapeutics Inc. building a consolidation baseGap Down & Free Long-Term Investment Growth Plans - newser.com
Aardvark Therapeutics Advances PWS Treatment with ARD-101 Study - TipRanks
Aardvark Therapeutics’ ARD-101 Study: A New Hope for Prader-Willi Syndrome - TipRanks
Finanzdaten der Aardvark Therapeutics Inc-Aktie (AARD)
Es liegen keine Finanzdaten für Aardvark Therapeutics Inc (AARD) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):